论文部分内容阅读
目的探讨吉非替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法将我院2008年9月到2010年10月收治的NSCLC患者42例,随机分为对照组与观察组,对照组20例采用常规的吉西他滨加顺铂治疗;观察组22例给予吉非替尼治疗,观察两组治疗后的症状改善情况、临床疗效及不良反应情况,并进行统计分析。结果观察组经2个周期治疗后,咳嗽、气急、血痰及胸痛等症状改善情况均优于对照组(P<0.05或P<0.01);观察组总有效率、Ⅲb期有效率、Ⅳ期有效率、1年生存率及平均存活时间均高于对照组(P<0.05);观察组常见的不良反应是皮疹和腹泻,除此之外,其不良反应发生率明显低于对照组(P<0.01)结论吉非替尼治疗晚期非小细胞肺癌的临床疗效确切,不良反应小,值得推广应用。
Objective To investigate the clinical efficacy of gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Forty-two patients with NSCLC admitted from September 2008 to October 2010 in our hospital were randomly divided into control group and observation group, 20 cases in control group received routine gemcitabine plus cisplatin, and 22 cases in observation group received gefitinib Ni treatment, observation of the two groups after treatment to improve the symptoms, clinical efficacy and adverse reactions, and statistical analysis. Results The improvement of cough, shortness of breath, bloody sputum and chest pain in the observation group after 2 cycles were better than those in the control group (P <0.05 or P <0.01). The total effective rate in the observation group, the effective rate in Ⅲ b phase, Efficiency, 1-year survival rate and mean survival time were higher than those in the control group (P <0.05). Adverse reactions observed in the observation group were rash and diarrhea. Besides, the incidence of adverse reactions was significantly lower than that of the control group (P < 0.01) Conclusion The clinical efficacy of gefitinib in the treatment of advanced non-small cell lung cancer is definite and the adverse reaction is small, which is worth popularizing and applying.